Advance Pharmaceutical
United States 3 duplicate records merged Updated 9 July 2026
Advance Pharmaceutical is a finished-dose manufacturer based in United States. It appears in 259 regulatory filings across 2 regulators, without an active US DMF or CEP on file. Its filings concentrate with DH (HK) and NMPA (CN). Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 27 February 2025 as VAI.
1
registered plants
1 with an FDA FEI number
259
filings
across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 27 February 2025 VAI US FDA
- 13 December 2018 VAI US FDA
- 6 July 2017 VAI US FDA
- 2 December 2015 OAI US FDA
- 6 March 2015 VAI US FDA
- 19 December 2013 VAI US FDA
- 2 July 2013 OAI US FDA
- 11 January 2013 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Holtsville, United States | 2434807 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| DH (HK) | 255 | None |
| NMPA (CN) | 4 | None |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Advance Pharmaceutical comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 27 February 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates